Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata (THRIVE-AA1)

NCT04518995 is registered in ClinicalTrials.gov with Concert Pharmaceuticals as lead sponsor.

NCT NCT04518995
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04518995 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata (THRIVE-AA1)
Lead sponsor
Concert Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
November 23, 2020
Completion date
April 19, 2022
Enrollment
706 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

alopecia areata